LSV Asset Management Buys New Shares in PetIQ, Inc. (NASDAQ:PETQ)

LSV Asset Management bought a new stake in PetIQ, Inc. (NASDAQ:PETQ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 43,005 shares of the company’s stock, valued at approximately $849,000. LSV Asset Management owned approximately 0.15% of PetIQ at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. DekaBank Deutsche Girozentrale bought a new position in PetIQ during the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of PetIQ by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,372 shares of the company’s stock valued at $67,000 after acquiring an additional 2,625 shares during the period. SG Americas Securities LLC bought a new stake in shares of PetIQ in the 3rd quarter worth about $113,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of PetIQ during the 4th quarter worth about $177,000. Finally, Olympiad Research LP acquired a new position in PetIQ in the third quarter valued at about $205,000. Institutional investors own 94.99% of the company’s stock.

PetIQ Stock Up 5.9 %

NASDAQ PETQ opened at $18.69 on Friday. The stock has a market capitalization of $550.07 million, a P/E ratio of 311.50 and a beta of 1.68. PetIQ, Inc. has a 52 week low of $11.92 and a 52 week high of $22.98. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.43 and a current ratio of 2.27. The stock has a fifty day moving average of $17.06 and a 200-day moving average of $17.99.

PetIQ (NASDAQ:PETQ) last issued its earnings results on Wednesday, February 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.22. PetIQ had a net margin of 0.19% and a return on equity of 11.72%. The company had revenue of $219.93 million for the quarter, compared to analyst estimates of $189.70 million. On average, equities research analysts forecast that PetIQ, Inc. will post 0.94 EPS for the current year.

Analyst Ratings Changes

Separately, Jefferies Financial Group increased their price target on PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, PetIQ has an average rating of “Buy” and an average target price of $29.00.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.